Research workbench
Deacetoxycephalosporin C synthase complexed with succinate
Analyse Deacetoxycephalosporin C synthase complexed with succinate in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.
- PDB
- 1UO9
- Type
- protein
- Length
- 282 residues
- Chains
- 1
- Method
- x-ray diffraction
- Collection
- MolNFT v1 / PDB
- Contract
- 0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
- Owner
- 0x3396CDB397284571d12822B4ae1189a8E22AAAAA
- Molecule
- Deacetoxycephalosporin C synthetase
- EC
- 1.14.20.1
- UniProt
- P18548
- Ligands
- FE2
- Pockets
- 2 · best druggability 0.65
Structure
x-ray diffraction · 1 distinct chain · 32% helix, 25% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| A | Deacetoxycephalosporin C synthetase (EC 1.14.20.1) | protein | 282 | 32% helix, 25% strand | P18548 |
Ligands and binding sites
Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.
Pockets
2 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 215 | 0.65 | 0.83 | 25 | FE2, SIN |
| 2 | 58 | 0.26 | 0.72 | 20 | empty |
Compared structures
- 1UO9 · Deacetoxycephalosporin C synthase complexed with succinate · the same entry in another collection · chain A against A, TM-score 1.00
- P18548 · AlphaFold monomer V2.0 prediction for deacetoxycephalosporin C synthase (P18548) · a predicted model of the same protein · chain A against A, TM-score 0.90
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Every structure of UniProt P18548
- Elsewhere: RCSB PDB 1UO9 · PDBe 1UO9 · UniProt P18548
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.